Biotech Mergers: Evaluating Risk, Reporting, and Integration of Growth Strategies : Gilead’s Acquisition of Immunomedics: Risk and a Growth Strategy . AEJ. 2025;33. Accessed August 15, 2026. https://www.aejournal.com/ojs/index.php/aej/article/view/1044